Allogene Therapeutics Inc (ALLO) stock saw a decline, ending the day at $2.16 which represents a decrease of $-0.04 or -1.82% from the prior close of $2.2. The stock opened at $2.21 and touched a low ...

ALLO Fiber has announced construction will soon begin this spring on a network build in the city of Boulder, Colorado.

Oppenheimer has recently resumed Allogene Therapeutics Inc (ALLO) stock to Outperform rating, as announced on August 8, 2024, according to Finviz. Earlier, on May 31, 2024, Piper Sandler had initiated ...

SOUTH SAN FRANCISCO, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T ...

From the focus program Bay High to a gap-year program for high school graduates, The Bay in Lincoln is giving young people ...

In 2025, keep an eye out for more "Severance," "Stranger Things," "The Bear," "The Last of Us," "Squid Game," and so much ...

The final of the EA Sports FC Supercup 2024/25 will be played on Monday 6 January 2024 at 20:00 CET (22:00 in Saudi Arabia) ...

During the Vietnam War, many SKS carbines were recorded as being “Russian” in origin, but recent research by archivists and ...

CNTY-101 is under clinical development by Century Therapeutics and currently in Phase I for Lupus Nephritis. According to GlobalData, Phase I drugs for Lupus Nephritis have an 84% phase transition ...

Amesanar is under clinical development by RHEACELL and currently in Phase II for Diabetic Foot Ulcers. According to GlobalData, Phase II drugs for Diabetic Foot Ulcers does not have sufficient ...